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1650Objective: The purpose of this study was to evaluate the efficacy and safety of bronchoscopic argon plasma
coagulation for tumorous endobronchial tuberculosis.
Methods:We analyzed the records of 115 patients with tumorous endobronchial tuberculosis who did not show
luminal narrowing of the bronchus at diagnosis. Of these 115 patients, 41 patients received bronchoscopic argon
plasma coagulation plus routine antituberculosis chemotherapy (argon plasma coagulation group) and the other
74 patients received only routine antituberculosis chemotherapy (chemotherapy group). The treatment effects
between these 2 groups were compared based on changes in lesions, rate of lesion disappearance, and compli-
cations associated with bronchoscopic argon plasma coagulation.
Results: The complete removal rate was 100% in patients in argon plasma coagulation group. About 84.6%
lesions disappeared completely in patients in the chemotherapy group. The rate of disappearance of lesions
in the argon plasma coagulation group was faster than that of the chemotherapy group. There were no severe
complications in the argon plasma coagulation group.
Conclusions: Bronchoscopic argon plasma coagulation can accelerate the healing of tumorous endobronchial
tuberculosis and can help prevent progressive bronchial stenosis resulting from tumorous endobronchial tuber-
culosis, and it is a very safe method. (J Thorac Cardiovasc Surg 2013;145:1650-3)Endobronchial tuberculosis (EBTB) is defined as a tubercu-
lous infection of the tracheobronchial tree with microbial
and histopathologic evidence. EBTB was divided mainly
into 7 types according bronchoscopic features: actively
caseating, edematous–hyperemic, fibrostenotic, tumorous,
granular, ulcerative, and nonspecific bronchitic. And a cer-
tain proportion of tumorous EBTB changed into the fibros-
tenotic type.1,2
The most important sequela of EBTB is bronchial steno-
sis, which causes wheezing, dyspnea, and obstructive pneu-
monia. Various bronchoscopic techniques applied to treat
stenotic lesions include laser and cryosurgery through
a fiber-optic bronchoscope.3-5 Granted bronchoscopic
treatment may have some efficacy, there still have been
no reports of the use of argon plasma coagulation (APC)
in patients with EBTB, but without luminal narrowing at
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needs to be clarified.
In this study, we analyzed the records from our hospital of
115 patients with tumorous EBTB to assess the efficacy and
safety of bronchoscopic APC treatment.METHODS
Study Subjects
Before June 2007, we applied routine antituberculosis chemotherapy
alone for tumorous EBTB. Several cases developed into bronchial stenosis
during the course of treatment. We applied APC in these cases and they got
completely cured at last. Then, after June 2007, we began to apply APC for
tumorous EBTB patients with no bronchial stenosis. We analyzed the re-
cords of 241 patients who were diagnosed as and treated for tumorous
EBTB in our department from February 2004 through January 2009.
The study was approved by the medical ethics committee of the Fourth
Military Medical University. The two diagnostic criteria of tumorous
EBTB and categories for patient selection were as follows:
1. Diagnosis of tuberculosis was confirmed by microbiologic or histopath-
ologic examination. All patients underwent bacteriologic studies of spu-
tum and bronchoscopic aspirates, and they also underwent pathologic
studies of bronchoscopic biopsy specimens.
2. The tumorous EBTB was defined according to the work of Chung and
Lee,1 as shown in Figure 1.
We selected 115 patients in our study. Inclusion criteria were as follows:
(1) the sputum smears were positive for tubercle bacillus, (2) the sputum
culture showed no multidrug-resistant tuberculosis (MDR-TB), and (3)
the treatment and follow-up were completed. The exclusion criteria were
as follows: (1) patients had an antituberculous medication history when
they presented to us, (2) patients had other subtypes of EBTB or it had al-
ready developed into bronchial stenosis, (3) the sputum culture showedgery c June 2013
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MDR-TB ¼ multidrug-resistant tuberculosis
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or follow-up.
In this study, multidrug resistance was referred to as any combination of
resistance to rifampicin, isoniazid, or ethambutol.
Treatment Procedure
Endobronchial APC was performed with an APC unit (ARCO 3000;
Soring Co, Quickborn, Germany) via an electronic bronchoscope (model
BF-260; Olympus Co, Tokyo, Japan). Energy at 30 to 40 W and argon
flow at 0.3 to 2.0 L/min was applied through a 2.0-mm diameter,
150-cm-long APC monopolar probe. The probe was inserted through the
working channel of the bronchoscope. The APC probe was positioned
1 to 2 mm away from the mucosa, and 1- to 2-second pulses of ablation
were repeated until the lesion was coagulated. The devitalized tissue was
removed mechanically with grasping forceps. Bronchoscopic APC was
performed every 2 weeks and was terminated when there was no tumorous
bronchial tuberculosis lesions observed.
Routine antituberculosis chemotherapy was the conventional combina-
tion of isoniazid, rifampicin, ethambutol, and pyrazinamide for 2 months
followed by isoniazid and rifampicin for another 4 months.
Bronchoscopic Examination and Follow-up
These patients received bronchoscopic examination every 2 weeks from
the beginning of the treatment for 6 months. Then, 6 months later, the pa-
tients received a bronchoscopic examination once every month for 3
months.
Outcome Events
The outcome measures were the lesion changes, the lesion disappear-
ance rate, and the complications of bronchoscopic APC. The changes in le-
sion were categorized into 4 groups: (1) improved, the number and/or the
volume of lesions was reduced; (2) healed, the lesions were removed com-
pletely; (3) stationary, there were no changes in the number and/or the vol-
ume of the lesions; and (4) worsened, the volume and/or the number of
lesions increased.FIGURE 1. Bronchoscopic featuring and treatment result of tumorous endobro
tuberculosis. Middle, Treating the lesion. Right, Treatment result.
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Of the 115 patients, 41 received bronchoscopic APC plus
routine antituberculosis chemotherapy and 74 received only
the routine antituberculosis chemotherapy. Table 1 shows
the characteristics of the study population. The main symp-
toms were fever, irritating cough, and chest pain. Neither
dyspnea nor obstructive pneumonia was seen at patient pre-
sentation. Figure 1 shows the features of tumorous EBTB,
treatment of bronchoscopic APC, and the treatment result
of the lesion.
Localization of Lesions
There were 180 lesions found in these 115 patients. The
localization and number of lesions were as follows: trachea,
7 (3.9%); left main bronchus, 52 (28.9%); left upper lobar
bronchus, 28 (15.6%); left lingual lobar bronchus, 13 (7.2%);
left lower lobar bronchus, 20 (11.1%); right main bronchus,
17 (9.4%); right upper lobar bronchus, 15 (8.3%); right
middle lobar bronchus, 15 (8.3%); right lower lobar bron-
chus, 13 (7.2%).
Change in Lesions
Of those 74 patients in the conventional chemotherapy
group, 62 patients were healed completely, with a treatment
duration of 5 months. The lesions in the remaining 12 pa-
tients showed no improvement after 4 months of treatment.
To remove the lesions in these 12 patients, we applied APC
and the lesions healed completely (Table 2).
Of those patients in the APC group, the mean APC treat-
ment was about 3, and all these patients healed completely.
The duration from the start of therapy to the complete
disappearance of lesions was about 1.5 months. No stenosis
appeared afterward.
Follow-up Result
Six months later, the patients received bronchoscopic ex-
amination once every month for 3 months. No lesion recur-
rence was observed.nchial tuberculosis. Left, Bronchoscopic feature of tumorous endobronchial
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TABLE 1. Clinical characteristics of 115 patients
Characteristic
Bronchoscopic
APCþ
chemotherapy
Antituberculosis
chemotherapy
alone
Sex
Female, n (%) 30 (73.1%) 48 (64.9%)
Age, y, mean  SD 30.2  10.4 33.1  11.3
Location of airway lesions,
n (%)
Trachea 2 (3.5%) 5 (4.1%)
Right main bronchus 5 (8.8%) 12 (9.8%)
Right upper lobar bronchus 7 (12.3%) 8 (6.5%)
Right middle lobar bronchus 5 (8.8%) 10 (8.1%)
Right lower lobar bronchus 3 (5.3%) 10 (8.1%)
Left main bronchus 19 (33.3%) 33 (26.8%)
Left upper lobar bronchus 8 (14.0%) 20 (16.3%)
Left lingual lobar bronchus 2 (3.5%) 11 (8.9%)
Left lower bronchus 6 (10.5%) 14 (11.4%)
APC, Argon plasma coagulation.
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During our APC treatment, complications included la-
ryngeal spasm (1/41, 2.4%), cough (35/41, 85.4%), and
a small amount of bleeding (5-10 mL; 5/41, 12.2%). No
secondary pulmonary infection, esphagotrachea fistula,
pneumothorax, trachea perforation, or death occurred.
DISCUSSION
Endobronchial tuberculosis has been reported in 10% to
37% of patients with pulmonary tuberculosis, and>90% of
the patients with tracheobronchial tuberculosis have some
degree of bronchial stenosis.6-8 In recent years, the
incidence of pulmonary tuberculosis shows an increasing
tendency in China,9 which results in an increasing incidence
of tracheobronchial tuberculosis. Despite adequate antitu-
berculosis chemotherapy, the tracheobronchial tuberculous
lesions in many patients heal by fibrostenosis,10,11 which
results in bronchial obstruction and various complications
such as atelectasis and obstructive pneumonia. Thus, it is
important to prevent bronchial stenosis and complications
in patients with EBTB.
With the development of interventional bronchoscopic
techniques, many new methods such as laser, APC, and
stent are used to treat bronchial stenosis.12 Until now, the lit-
erature reported that these treatment methods were not
applied until the stenosis occurred.TABLE 2. Bronchoscopic findings of these 2 groups of patients
Time point (wk)
APCþchemotherapy, n
Healed Improved No change W
4 15 26 0
8 41 0 0
12 41 0 0
16 41 0 0
APC, Argon plasma coagulation.
1652 The Journal of Thoracic and Cardiovascular SurIn APC, a high-frequency electrical current is trans-
ferred from the probe tip through ionized argon gas,
without contact with the tissue, resulting in superficial
thermal coagulation. The procedure is very effective
for hemostasis, and the visible ionized argon plasma
can be guided visually. The penetration depth of about
2 mm is broadly constant and predictable, and limits
thermal trauma, thereby avoiding unnecessary damage
to the airway cartilage and connective tissue. APC also
has advantages such as mobility and a lower cost than
other commonly used modalities.
Whether APC can help prevent tumorous EBTB from
progressing to stenosis needs to be clarified. To this end,
we analyzed the treatment records of 115 patients with tu-
morous EBTB in our hospital to determine the efficacy
and safety of bronchoscopic APC treatment. In our study,
of the 41 patients in the APC plus antituberculosis group,
all patients healed completely. After 4 weeks, about
36.6% of the patients in the APCþ chemotherapy group
were healed whereas about 10.8% of chemotherapy-alone
group were healed. At 16 weeks, all patients in the
APCþchemotherapy group were healed completely whereas
about 67.6% of patients in the chemotherapy-alone group
were healed. Therefore, we believe that the APC treatment
can prevent bronchial stenosis caused by tumorous EBTB
and can accelerate the rate of healing in contrast with anti-
tuberculosis chemotherapy alone.
Granted, our study shows that APC accelerates the rate of
healing of tumorous EBTB, but additional study could in-
clude investigations into the efficacy of a shorter systemic
treatment to avoid toxicity, although we do not believe sys-
temic treatment can be administered for a shorter period of
time. In our experience, some patients terminated systemic
treatment themselves. Unfortunately, the lesions in all these
patients recurred.
The cases had not showed bronchial stenosis, under this
circumstance, lung function might not be a sensitive mea-
surement to judge the patients’ condition, so we did not
perform the lung function test for the patients. Whether
lung function was impaired by this kind tumorous EBTB
or improved by our treatment needs to be studied further.
The complications caused by the use of bronchoscopy
have a trend to increase during these years,13 but in our
study no severe complications occurred during the APC
treatments. During our treatment, the main complicationsChemotherapy alone, n
orse Healed Improved No change Worse
0 8 52 11 3
0 21 41 9 3
0 33 29 9 3
0 50 12 9 3
gery c June 2013
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ing. The main reason for laryngospasm was because of
insufficient anesthesia and violent insertion of the broncho-
scope, which stimulated the vocal cords. This complication
also occurred during other bronchoscopic procedures and
we reasoned it had no relationship with APC. The cough ob-
served during APC was stimulated by the gasified tissues
but did not make these patients suffer much. The bleeding
could be stopped by the APC treatment itself. Although
APC caused no severe complications, the bronchoscopic
operation itself had some risks. If the patients had severe
underlying diseases such as heart failure or a bleeding ten-
dency, we would not use APC. Although our results are
promising, in that we observed patients for 9 months, it is
our opinion that long-term follow-up should be done and
add additional support to our findings. From our study we
deem that APC could be considered an effective and safe
method for management of tumorous EBTB.References
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